Cidara Therapeutics - Stock Price History | CDTX

Historical daily share price chart and data for Cidara Therapeutics since 2023 adjusted for splits. The latest closing stock price for Cidara Therapeutics as of January 27, 2023 is 1.21.
  • The all-time high Cidara Therapeutics stock closing price was 17.26 on December 30, 2015.
  • The Cidara Therapeutics 52-week high stock price is 1.60, which is 32.2% above the current share price.
  • The Cidara Therapeutics 52-week low stock price is 0.40, which is 66.9% below the current share price.
  • The average Cidara Therapeutics stock price for the last 52 weeks is 0.69.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Cidara Therapeutics Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2022 0.6878 1.3900 1.3900 0.4280 0.7563 -40.45%
2021 2.0042 2.0600 3.0100 1.1800 1.2700 -36.50%
2020 3.0633 3.4100 4.2600 1.7400 2.0000 -47.92%
2019 2.1910 2.7000 3.8400 1.2500 3.8400 63.40%
2018 4.8665 6.9500 8.1500 2.1000 2.3500 -65.44%
2017 7.5928 10.1500 11.7000 5.7500 6.8000 -34.62%
2016 11.3948 16.9300 16.9300 8.7000 10.4000 -39.39%
2015 14.8686 16.0000 17.2600 12.4300 17.1600 0.00%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.087B $0.050B
Cidara Therapeutics, Inc. is a biotechnology company. The company is focused on the discovery, development and commercialization of novel anti-infectives. Its product pipeline includes CD101 IV, a long-acting echinocandin antifungal, CD101 topical and C001 which are in different clinical trial. The company developed its product using Cloudbreak(TM) immunotherapy platform. Cidara Therapeutics, Inc. is headquartered in San Diego, California.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $155.188B 9.47
GSK (GSK) United Kingdom $72.345B 9.01
Bio-Rad Laboratories (BIO.B) United States $12.069B 28.64
QIAGEN (QGEN) Netherlands $11.333B 19.34
Ginkgo Bioworks Holdings (DNA) United States $3.395B 0.00
Myovant Sciences (MYOV) United Kingdom $2.604B 0.00
Arcus Biosciences (RCUS) United States $1.672B 25.10
Biohaven (BHVN) United States $1.264B 0.00
Emergent Biosolutions (EBS) United States $0.655B 5.15
ADC Therapeutics SA (ADCT) Switzerland $0.363B 0.00
Ambrx Biopharma (AMAM) United States $0.073B 0.00
Enzo Biochem (ENZ) United States $0.073B 0.00
Gelesis Holdings (GLS) United States $0.027B 0.00
SQZ Biotechnologies (SQZ) United States $0.025B 0.00